Global Immunomodulators Market Growth 2024-2030

The global Immunomodulators market size was valued at US$ 133,650 million in 2023. With growing demand in the downstream market, immunomodulators are expected to expand, driven by

Introduction Immunomodulators are referred to as the medications that are used for the regulation or for normalizing the immune system. Market Insights According to the Publishers’ latest study, the global Immunomodulators market size was valued at US$ 133650 million in 2023. With growing demand in downstream market, the Immunomodulators is forecast to a readjusted size of US$ 166360 million by 2030 with a CAGR of 3.2% during review period.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

The global market for immunomodulators is expected to grow exponentially over the forecast period owing to the rising cases of chronic diseases such as multiple sclerosis, allergic conditions, cancer, and asthma. Key Features: The report on Immunomodulators market reflects various aspects and provide valuable insights into the industry.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Trends: Increasing Prevalence of Autoimmune and Inflammatory Disorders: The growing incidence of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel diseases, has fuelled the demand for effective immunomodulatory therapies. Rise in Cancer Incidence and Adoption of Immuno-Oncology Treatments: The increasing prevalence of cancer and the growing acceptance of immunomodulators as part of cancer treatment regimens, particularly in immuno-oncology, have driven market growth. Advancements in Immunology and Biotechnology: Rapid advancements in immunology research, coupled with the development of innovative biotechnology platforms, have enabled the discovery and development of novel immunomodulatory agents. Shift Towards Targeted and Personalized Therapies: The market has witnessed a trend towards the development of targeted immunomodulators that can selectively modulate specific immune pathways, leading to more personalized and effective treatments. Expansion of Regulatory Approvals and Reimbursement Coverage: The increasing number of regulatory approvals for immunomodulatory drugs and the expansion of reimbursement coverage for these therapies have improved patient access and adoption. Growing Emphasis on Combination Therapies: The combination of immunomodulators with other treatment modalities, such as chemotherapy, targeted therapies, and other biologics, has become a widely adopted approach to enhance therapeutic efficacy. Drivers: Rising Prevalence of Autoimmune and Inflammatory Disorders: The growing incidence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and lupus, as well as inflammatory conditions, such as inflammatory bowel diseases, has increased the demand for effective immunomodulatory treatments. Increasing Incidence of Cancer and Adoption of Immuno-Oncology: The rising prevalence of various types of cancer and the growing acceptance of immunomodulators as part of cancer treatment regimens, particularly in the field of immuno-oncology, have fueled market growth. Advancements in Immunology Research and Biotechnology: Continuous advancements in the understanding of the immune system and the development of innovative biotechnology platforms have enabled the discovery and development of novel immunomodulatory agents. Favorable Regulatory Landscape and Reimbursement Policies: The increasing number of regulatory approvals for immunomodulatory drugs and the expansion of reimbursement coverage for these therapies have improved patient access and adoption. Unmet Medical Needs and the Demand for Improved Therapeutic Options: The limited efficacy and adverse effects associated with traditional treatment options for autoimmune, inflammatory, and oncological conditions have created a need for more effective and safer immunomodulatory therapies. Aging Population and the Rising Burden of Chronic Diseases: The aging population and the increasing prevalence of chronic diseases, including autoimmune disorders and cancer, have contributed to the growing demand for immunomodulatory treatments. Opportunities: Expansion into Emerging Markets: Developing economies in regions such as Asia-Pacific, Latin America, and the Middle East & Africa offer significant growth potential as the prevalence of autoimmune and inflammatory disorders, as well as cancer, continues to rise in these regions. Advancements in Targeted and Personalized Immunotherapies: The development of novel immunomodulators that can selectively target specific immune pathways or patient subgroups can lead to more personalized and effective treatments, addressing unmet medical needs. Combination Therapy Approaches: The integration of immunomodulators with other treatment modalities, such as chemotherapy, targeted therapies, and other biologics, can enhance therapeutic efficacy and open up new market opportunities. Expansion of Regulatory Approvals and Reimbursement Coverage: The continued expansion of regulatory approvals for immunomodulatory drugs and the increasing coverage of these therapies by public and private payers can enhance patient access and drive market growth. Leveraging Digital Health and Artificial Intelligence: The integration of digital health technologies and the application of artificial intelligence in the development, clinical trials, and patient monitoring of immunomodulatory therapies can improve efficiency and patient outcomes. Mergers, Acquisitions, and Collaborations: Increased merger and acquisition activities, as well as strategic collaborations between pharmaceutical companies, biotechnology firms, and research institutions, can facilitate the development and commercialization of innovative immunomodulatory products. Threats: Adverse Effects and Safety Concerns: Immunomodulatory agents can sometimes be associated with serious adverse effects, such as infections, autoimmune reactions, and cancer, which can limit their adoption and lead to regulatory scrutiny. Patent Expiration and Competition from Generics: The expiration of patents for certain immunomodulatory drugs can lead to increased competition from generic and biosimilar products, which may impact pricing and market share. Reimbursement Challenges and Cost Pressures: Healthcare systems and payers may face budgetary constraints, leading to increased scrutiny of the cost-effectiveness of immunomodulatory therapies and potential reimbursement challenges. Regulatory and Clinical Trial Complexities: The development and approval of immunomodulatory drugs can be hindered by the complexity of clinical trial designs, the need for extensive safety data, and stringent regulatory requirements. Evolving Standard of Care and Competitive Landscape: The continuously evolving standard of care in the treatment of autoimmune, inflammatory, and oncological conditions, as well as the entry of new competitive products, can create challenges for immunomodulators to maintain their market position. Market Size and Growth: The research report provide an overview of the current size and growth of the Immunomodulators market. It may include historical data, market segmentation by Type (e.g., Immunosuppressant, Immunostimulants), and regional breakdowns. Competitive Landscape: The research report provides analysis of the competitive landscape within the Immunomodulators market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Immunomodulators market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Immunomodulators market. The report also evaluates the effectiveness of these policies in driving market growth. Market Forecasts and Future Outlook: The global immunomodulators market presents a promising outlook, with significant growth potential driven by the increasing prevalence of autoimmune, inflammatory, and oncological conditions, advancements in immunology research and biotechnology, and the expanding role of immunomodulatory therapies in various therapeutic areas. Pharmaceutical and biotechnology companies that can effectively navigate the evolving market dynamics, invest in product innovation, and address the emerging challenges are well-positioned to capitalize on the opportunities in the global immunomodulators market. Market Segmentation: Immunomodulators market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. Segmentation by type Immunosuppressant Immunostimulants Segmentation by application Oncology Respiratory HIV Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Roche Amgen Inc. Abbott Johnson & Johnson Novartis AG Eli Lilly and Company Bristol-Myers Squibb Company Merck & Co. Inc. Biogen

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Immunomodulators Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Immunomodulators by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Immunomodulators by Country/Region, 2019, 2023 & 2030
  • 2.2 Immunomodulators Segment by Type
  • 2.2.1 Immunosuppressant
  • 2.2.2 Immunostimulants
  • 2.3 Immunomodulators Sales by Type
  • 2.3.1 Global Immunomodulators Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Immunomodulators Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Immunomodulators Sale Price by Type (2019-2024)
  • 2.4 Immunomodulators Segment by Application
  • 2.4.1 Oncology
  • 2.4.2 Respiratory
  • 2.4.3 HIV
  • 2.4.4 Others
  • 2.5 Immunomodulators Sales by Application
  • 2.5.1 Global Immunomodulators Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Immunomodulators Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Immunomodulators Sale Price by Application (2019-2024)
  • 3 Global Immunomodulators by Company
  • 3.1 Global Immunomodulators Breakdown Data by Company
  • 3.1.1 Global Immunomodulators Annual Sales by Company (2019-2024)
  • 3.1.2 Global Immunomodulators Sales Market Share by Company (2019-2024)
  • 3.2 Global Immunomodulators Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Immunomodulators Revenue by Company (2019-2024)
  • 3.2.2 Global Immunomodulators Revenue Market Share by Company (2019-2024)
  • 3.3 Global Immunomodulators Sale Price by Company
  • 3.4 Key Manufacturers Immunomodulators Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Immunomodulators Product Location Distribution
  • 3.4.2 Players Immunomodulators Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Immunomodulators by Geographic Region
  • 4.1 World Historic Immunomodulators Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Immunomodulators Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Immunomodulators Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Immunomodulators Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Immunomodulators Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Immunomodulators Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Immunomodulators Sales Growth
  • 4.4 APAC Immunomodulators Sales Growth
  • 4.5 Europe Immunomodulators Sales Growth
  • 4.6 Middle East & Africa Immunomodulators Sales Growth
  • 5 Americas
  • 5.1 Americas Immunomodulators Sales by Country
  • 5.1.1 Americas Immunomodulators Sales by Country (2019-2024)
  • 5.1.2 Americas Immunomodulators Revenue by Country (2019-2024)
  • 5.2 Americas Immunomodulators Sales by Type
  • 5.3 Americas Immunomodulators Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Immunomodulators Sales by Region
  • 6.1.1 APAC Immunomodulators Sales by Region (2019-2024)
  • 6.1.2 APAC Immunomodulators Revenue by Region (2019-2024)
  • 6.2 APAC Immunomodulators Sales by Type
  • 6.3 APAC Immunomodulators Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Immunomodulators by Country
  • 7.1.1 Europe Immunomodulators Sales by Country (2019-2024)
  • 7.1.2 Europe Immunomodulators Revenue by Country (2019-2024)
  • 7.2 Europe Immunomodulators Sales by Type
  • 7.3 Europe Immunomodulators Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Immunomodulators by Country
  • 8.1.1 Middle East & Africa Immunomodulators Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Immunomodulators Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Immunomodulators Sales by Type
  • 8.3 Middle East & Africa Immunomodulators Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Immunomodulators
  • 10.3 Manufacturing Process Analysis of Immunomodulators
  • 10.4 Industry Chain Structure of Immunomodulators
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Immunomodulators Distributors
  • 11.3 Immunomodulators Customer
  • 12 World Forecast Review for Immunomodulators by Geographic Region
  • 12.1 Global Immunomodulators Market Size Forecast by Region
  • 12.1.1 Global Immunomodulators Forecast by Region (2025-2030)
  • 12.1.2 Global Immunomodulators Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Immunomodulators Forecast by Type
  • 12.7 Global Immunomodulators Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Roche
  • 13.1.1 Roche Company Information
  • 13.1.2 Roche Immunomodulators Product Portfolios and Specifications
  • 13.1.3 Roche Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Roche Main Business Overview
  • 13.1.5 Roche Latest Developments
  • 13.2 Amgen Inc.
  • 13.2.1 Amgen Inc. Company Information
  • 13.2.2 Amgen Inc. Immunomodulators Product Portfolios and Specifications
  • 13.2.3 Amgen Inc. Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 Amgen Inc. Main Business Overview
  • 13.2.5 Amgen Inc. Latest Developments
  • 13.3 Abbott
  • 13.3.1 Abbott Company Information
  • 13.3.2 Abbott Immunomodulators Product Portfolios and Specifications
  • 13.3.3 Abbott Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 Abbott Main Business Overview
  • 13.3.5 Abbott Latest Developments
  • 13.4 Johnson & Johnson
  • 13.4.1 Johnson & Johnson Company Information
  • 13.4.2 Johnson & Johnson Immunomodulators Product Portfolios and Specifications
  • 13.4.3 Johnson & Johnson Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 Johnson & Johnson Main Business Overview
  • 13.4.5 Johnson & Johnson Latest Developments
  • 13.5 Novartis AG
  • 13.5.1 Novartis AG Company Information
  • 13.5.2 Novartis AG Immunomodulators Product Portfolios and Specifications
  • 13.5.3 Novartis AG Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.5.4 Novartis AG Main Business Overview
  • 13.5.5 Novartis AG Latest Developments
  • 13.6 Eli Lilly and Company
  • 13.6.1 Eli Lilly and Company Company Information
  • 13.6.2 Eli Lilly and Company Immunomodulators Product Portfolios and Specifications
  • 13.6.3 Eli Lilly and Company Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.6.4 Eli Lilly and Company Main Business Overview
  • 13.6.5 Eli Lilly and Company Latest Developments
  • 13.7 Bristol-Myers Squibb Company
  • 13.7.1 Bristol-Myers Squibb Company Company Information
  • 13.7.2 Bristol-Myers Squibb Company Immunomodulators Product Portfolios and Specifications
  • 13.7.3 Bristol-Myers Squibb Company Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.7.4 Bristol-Myers Squibb Company Main Business Overview
  • 13.7.5 Bristol-Myers Squibb Company Latest Developments
  • 13.8 Merck & Co. Inc.
  • 13.8.1 Merck & Co. Inc. Company Information
  • 13.8.2 Merck & Co. Inc. Immunomodulators Product Portfolios and Specifications
  • 13.8.3 Merck & Co. Inc. Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.8.4 Merck & Co. Inc. Main Business Overview
  • 13.8.5 Merck & Co. Inc. Latest Developments
  • 13.9 Biogen
  • 13.9.1 Biogen Company Information
  • 13.9.2 Biogen Immunomodulators Product Portfolios and Specifications
  • 13.9.3 Biogen Immunomodulators Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.9.4 Biogen Main Business Overview
  • 13.9.5 Biogen Latest Developments
  • 14 Research Findings and Conclusion

Table 1. Immunomodulators Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions) Table 2. Immunomodulators Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions) Table 3. Major Players of Immunosuppressant Table 4. Major Players of Immunostimulants Table 5. Global Immunomodulators Sales by Type (2019-2024) & (K Units) Table 6. Global Immunomodulators Sales Market Share by Type (2019-2024) Table 7. Global Immunomodulators Revenue by Type (2019-2024) & ($ million) Table 8. Global Immunomodulators Revenue Market Share by Type (2019-2024) Table 9. Global Immunomodulators Sale Price by Type (2019-2024) & (USD/Unit) Table 10. Global Immunomodulators Sales by Application (2019-2024) & (K Units) Table 11. Global Immunomodulators Sales Market Share by Application (2019-2024) Table 12. Global Immunomodulators Revenue by Application (2019-2024) Table 13. Global Immunomodulators Revenue Market Share by Application (2019-2024) Table 14. Global Immunomodulators Sale Price by Application (2019-2024) & (USD/Unit) Table 15. Global Immunomodulators Sales by Company (2019-2024) & (K Units) Table 16. Global Immunomodulators Sales Market Share by Company (2019-2024) Table 17. Global Immunomodulators Revenue by Company (2019-2024) ($ Millions) Table 18. Global Immunomodulators Revenue Market Share by Company (2019-2024) Table 19. Global Immunomodulators Sale Price by Company (2019-2024) & (USD/Unit) Table 20. Key Manufacturers Immunomodulators Producing Area Distribution and Sales Area Table 21. Players Immunomodulators Products Offered Table 22. Immunomodulators Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) Table 23. New Products and Potential Entrants Table 24. Mergers & Acquisitions, Expansion Table 25. Global Immunomodulators Sales by Geographic Region (2019-2024) & (K Units) Table 26. Global Immunomodulators Sales Market Share Geographic Region (2019-2024) Table 27. Global Immunomodulators Revenue by Geographic Region (2019-2024) & ($ millions) Table 28. Global Immunomodulators Revenue Market Share by Geographic Region (2019-2024) Table 29. Global Immunomodulators Sales by Country/Region (2019-2024) & (K Units) Table 30. Global Immunomodulators Sales Market Share by Country/Region (2019-2024) Table 31. Global Immunomodulators Revenue by Country/Region (2019-2024) & ($ millions) Table 32. Global Immunomodulators Revenue Market Share by Country/Region (2019-2024) Table 33. Americas Immunomodulators Sales by Country (2019-2024) & (K Units) Table 34. Americas Immunomodulators Sales Market Share by Country (2019-2024) Table 35. Americas Immunomodulators Revenue by Country (2019-2024) & ($ Millions) Table 36. Americas Immunomodulators Revenue Market Share by Country (2019-2024) Table 37. Americas Immunomodulators Sales by Type (2019-2024) & (K Units) Table 38. Americas Immunomodulators Sales by Application (2019-2024) & (K Units) Table 39. APAC Immunomodulators Sales by Region (2019-2024) & (K Units) Table 40. APAC Immunomodulators Sales Market Share by Region (2019-2024) Table 41. APAC Immunomodulators Revenue by Region (2019-2024) & ($ Millions) Table 42. APAC Immunomodulators Revenue Market Share by Region (2019-2024) Table 43. APAC Immunomodulators Sales by Type (2019-2024) & (K Units) Table 44. APAC Immunomodulators Sales by Application (2019-2024) & (K Units) Table 45. Europe Immunomodulators Sales by Country (2019-2024) & (K Units) Table 46. Europe Immunomodulators Sales Market Share by Country (2019-2024) Table 47. Europe Immunomodulators Revenue by Country (2019-2024) & ($ Millions) Table 48. Europe Immunomodulators Revenue Market Share by Country (2019-2024) Table 49. Europe Immunomodulators Sales by Type (2019-2024) & (K Units) Table 50. Europe Immunomodulators Sales by Application (2019-2024) & (K Units) Table 51. Middle East & Africa Immunomodulators Sales by Country (2019-2024) & (K Units) Table 52. Middle East & Africa Immunomodulators Sales Market Share by Country (2019-2024) Table 53. Middle East & Africa Immunomodulators Revenue by Country (2019-2024) & ($ Millions) Table 54. Middle East & Africa Immunomodulators Revenue Market Share by Country (2019-2024) Table 55. Middle East & Africa Immunomodulators Sales by Type (2019-2024) & (K Units) Table 56. Middle East & Africa Immunomodulators Sales by Application (2019-2024) & (K Units) Table 57. Key Market Drivers & Growth Opportunities of Immunomodulators Table 58. Key Market Challenges & Risks of Immunomodulators Table 59. Key Industry Trends of Immunomodulators Table 60. Immunomodulators Raw Material Table 61. Key Suppliers of Raw Materials Table 62. Immunomodulators Distributors List Table 63. Immunomodulators Customer List Table 64. Global Immunomodulators Sales Forecast by Region (2025-2030) & (K Units) Table 65. Global Immunomodulators Revenue Forecast by Region (2025-2030) & ($ millions) Table 66. Americas Immunomodulators Sales Forecast by Country (2025-2030) & (K Units) Table 67. Americas Immunomodulators Revenue Forecast by Country (2025-2030) & ($ millions) Table 68. APAC Immunomodulators Sales Forecast by Region (2025-2030) & (K Units) Table 69. APAC Immunomodulators Revenue Forecast by Region (2025-2030) & ($ millions) Table 70. Europe Immunomodulators Sales Forecast by Country (2025-2030) & (K Units) Table 71. Europe Immunomodulators Revenue Forecast by Country (2025-2030) & ($ millions) Table 72. Middle East & Africa Immunomodulators Sales Forecast by Country (2025-2030) & (K Units) Table 73. Middle East & Africa Immunomodulators Revenue Forecast by Country (2025-2030) & ($ millions) Table 74. Global Immunomodulators Sales Forecast by Type (2025-2030) & (K Units) Table 75. Global Immunomodulators Revenue Forecast by Type (2025-2030) & ($ Millions) Table 76. Global Immunomodulators Sales Forecast by Application (2025-2030) & (K Units) Table 77. Global Immunomodulators Revenue Forecast by Application (2025-2030) & ($ Millions) Table 78. Roche Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 79. Roche Immunomodulators Product Portfolios and Specifications Table 80. Roche Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 81. Roche Main Business Table 82. Roche Latest Developments Table 83. Amgen Inc. Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 84. Amgen Inc. Immunomodulators Product Portfolios and Specifications Table 85. Amgen Inc. Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 86. Amgen Inc. Main Business Table 87. Amgen Inc. Latest Developments Table 88. Abbott Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 89. Abbott Immunomodulators Product Portfolios and Specifications Table 90. Abbott Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 91. Abbott Main Business Table 92. Abbott Latest Developments Table 93. Johnson & Johnson Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 94. Johnson & Johnson Immunomodulators Product Portfolios and Specifications Table 95. Johnson & Johnson Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 96. Johnson & Johnson Main Business Table 97. Johnson & Johnson Latest Developments Table 98. Novartis AG Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 99. Novartis AG Immunomodulators Product Portfolios and Specifications Table 100. Novartis AG Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 101. Novartis AG Main Business Table 102. Novartis AG Latest Developments Table 103. Eli Lilly and Company Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 104. Eli Lilly and Company Immunomodulators Product Portfolios and Specifications Table 105. Eli Lilly and Company Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 106. Eli Lilly and Company Main Business Table 107. Eli Lilly and Company Latest Developments Table 108. Bristol-Myers Squibb Company Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 109. Bristol-Myers Squibb Company Immunomodulators Product Portfolios and Specifications Table 110. Bristol-Myers Squibb Company Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 111. Bristol-Myers Squibb Company Main Business Table 112. Bristol-Myers Squibb Company Latest Developments Table 113. Merck & Co. Inc. Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 114. Merck & Co. Inc. Immunomodulators Product Portfolios and Specifications Table 115. Merck & Co. Inc. Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 116. Merck & Co. Inc. Main Business Table 117. Merck & Co. Inc. Latest Developments Table 118. Biogen Basic Information, Immunomodulators Manufacturing Base, Sales Area and Its Competitors Table 119. Biogen Immunomodulators Product Portfolios and Specifications Table 120. Biogen Immunomodulators Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024) Table 121. Biogen Main Business Table 122. Biogen Latest Developments

Figure 1. Picture of Immunomodulators Figure 2. Immunomodulators Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Immunomodulators Sales Growth Rate 2019-2030 (K Units) Figure 7. Global Immunomodulators Revenue Growth Rate 2019-2030 ($ Millions) Figure 8. Immunomodulators Sales by Region (2019, 2023 & 2030) & ($ Millions) Figure 9. Product Picture of Immunosuppressant Figure 10. Product Picture of Immunostimulants Figure 11. Global Immunomodulators Sales Market Share by Type in 2023 Figure 12. Global Immunomodulators Revenue Market Share by Type (2019-2024) Figure 13. Immunomodulators Consumed in Oncology Figure 14. Global Immunomodulators Market: Oncology (2019-2024) & (K Units) Figure 15. Immunomodulators Consumed in Respiratory Figure 16. Global Immunomodulators Market: Respiratory (2019-2024) & (K Units) Figure 17. Immunomodulators Consumed in HIV Figure 18. Global Immunomodulators Market: HIV (2019-2024) & (K Units) Figure 19. Immunomodulators Consumed in Others Figure 20. Global Immunomodulators Market: Others (2019-2024) & (K Units) Figure 21. Global Immunomodulators Sales Market Share by Application (2023) Figure 22. Global Immunomodulators Revenue Market Share by Application in 2023 Figure 23. Immunomodulators Sales Market by Company in 2023 (K Units) Figure 24. Global Immunomodulators Sales Market Share by Company in 2023 Figure 25. Immunomodulators Revenue Market by Company in 2023 ($ Million) Figure 26. Global Immunomodulators Revenue Market Share by Company in 2023 Figure 27. Global Immunomodulators Sales Market Share by Geographic Region (2019-2024) Figure 28. Global Immunomodulators Revenue Market Share by Geographic Region in 2023 Figure 29. Americas Immunomodulators Sales 2019-2024 (K Units) Figure 30. Americas Immunomodulators Revenue 2019-2024 ($ Millions) Figure 31. APAC Immunomodulators Sales 2019-2024 (K Units) Figure 32. APAC Immunomodulators Revenue 2019-2024 ($ Millions) Figure 33. Europe Immunomodulators Sales 2019-2024 (K Units) Figure 34. Europe Immunomodulators Revenue 2019-2024 ($ Millions) Figure 35. Middle East & Africa Immunomodulators Sales 2019-2024 (K Units) Figure 36. Middle East & Africa Immunomodulators Revenue 2019-2024 ($ Millions) Figure 37. Americas Immunomodulators Sales Market Share by Country in 2023 Figure 38. Americas Immunomodulators Revenue Market Share by Country in 2023 Figure 39. Americas Immunomodulators Sales Market Share by Type (2019-2024) Figure 40. Americas Immunomodulators Sales Market Share by Application (2019-2024) Figure 41. United States Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 42. Canada Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 43. Mexico Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 44. Brazil Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 45. APAC Immunomodulators Sales Market Share by Region in 2023 Figure 46. APAC Immunomodulators Revenue Market Share by Regions in 2023 Figure 47. APAC Immunomodulators Sales Market Share by Type (2019-2024) Figure 48. APAC Immunomodulators Sales Market Share by Application (2019-2024) Figure 49. China Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 50. Japan Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 51. South Korea Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 52. Southeast Asia Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 53. India Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 54. Australia Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 55. China Taiwan Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 56. Europe Immunomodulators Sales Market Share by Country in 2023 Figure 57. Europe Immunomodulators Revenue Market Share by Country in 2023 Figure 58. Europe Immunomodulators Sales Market Share by Type (2019-2024) Figure 59. Europe Immunomodulators Sales Market Share by Application (2019-2024) Figure 60. Germany Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 61. France Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 62. UK Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 63. Italy Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 64. Russia Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 65. Middle East & Africa Immunomodulators Sales Market Share by Country in 2023 Figure 66. Middle East & Africa Immunomodulators Revenue Market Share by Country in 2023 Figure 67. Middle East & Africa Immunomodulators Sales Market Share by Type (2019-2024) Figure 68. Middle East & Africa Immunomodulators Sales Market Share by Application (2019-2024) Figure 69. Egypt Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 70. South Africa Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 71. Israel Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 72. Turkey Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 73. GCC Country Immunomodulators Revenue Growth 2019-2024 ($ Millions) Figure 74. Manufacturing Cost Structure Analysis of Immunomodulators in 2023 Figure 75. Manufacturing Process Analysis of Immunomodulators Figure 76. Industry Chain Structure of Immunomodulators Figure 77. Channels of Distribution Figure 78. Global Immunomodulators Sales Market Forecast by Region (2025-2030) Figure 79. Global Immunomodulators Revenue Market Share Forecast by Region (2025-2030) Figure 80. Global Immunomodulators Sales Market Share Forecast by Type (2025-2030) Figure 81. Global Immunomodulators Revenue Market Share Forecast by Type (2025-2030) Figure 82. Global Immunomodulators Sales Market Share Forecast by Application (2025-2030) Figure 83. Global Immunomodulators Revenue Market Share Forecast by Application (2025-2030)
Logo

Global Immunomodulators Market Growth 2024-2030

Contact usWe are friendly and approachable, give us a call.